NEW YORK (GenomeWeb) – Cancer diagnostics firm Signal Genetics on Thursday reported an 18 percent year-over-year increase in its second quarter revenues.

In a form 10-Q filed with the US Securities and Exchange Comission, the New York-based company, which went public in June, said that it had revenues of $1.3 million for the three months ended June 30,, compared to $1.1 million in the year-ago quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.